Sugi Predict

Sugi Predict / Compounds / SCHEMBL298303

SCHEMBL298303

SCHEMBL298303

CCCCCCCCCCC(CCCCCCCCCCCCCCCC(=O)O)(CCCCCCCCCCCCCC(=O)O)C(=O)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MBOAT4 Q96T53 1/20 0.47
▸ CETP P11597 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ TSHR P16473 5/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ TDP1 Q9NUW8 3/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ MAPT P10636 1/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.45
▸ PPARG P37231 6/20 0.45
▸ PPARD Q03181 6/20 0.45
▸ PPARA Q07869 6/20 0.45
▸ HDAC11 Q96DB2 5/20 0.45
▸ GPR84 Q9NQS5 4/20 0.45
▸ TLR2 O60603 2/20 0.45
▸ FABP4 P15090 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL27916246 0.86 CETP (0.49) MBOAT4CETPMEN1KMT2ATSHR
SCHEMBL16429638 0.83 ALDH1A1 (0.47) MBOAT4CETPMEN1KMT2ATSHR
SCHEMBL7541915 0.82 CETP (0.52) MBOAT4CETPMEN1KMT2ATSHR
SCHEMBL7537786 0.82 CETP (0.52) MBOAT4CETPMEN1KMT2ATSHR
Dodecanoate SCHEMBL9956947 0.82 PAM (0.54) CETPMEN1KMT2AHTTTSHR
Myristic Acid SCHEMBL29874573 0.82 PAM (0.54) CETPMEN1KMT2AHTTTSHR
SCHEMBL284241 0.81 ALDH1A1 (0.50) KMT2AHTTALDH1A1TDP1MAPK1
SCHEMBL7499996 0.81 PLA2G4B (0.50) ALDH1A1L3MBTL1PPARA
Undecanoate SCHEMBL8164855 0.81 CETP (0.51) CETPMEN1KMT2AHTTTSHR
SCHEMBL29414961 0.81 CETP (0.51) MBOAT4CETPMEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080233067-A1 Method Of Making Enhanced Efficacy Antiperspirant Actives COLGATE-PALMOLIVE COMPANY (US) 2008-09-25 — — US claimed
US-20230414512-A1 Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same LABORATORY SKIN CARE, INC. 2023-12-28 — — US disclosed
EP-4218718-A2 DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME Laboratory Skin Care, Inc. (US) 2023-08-02 — — EP disclosed
EP-2427178-B1 DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME LABORATORY SKIN CARE INC (US) 2023-01-04 — — EP disclosed
US-20210220276-A1 Methods of Treating Skin LABORATORY SKIN CARE, INC. 2021-07-22 — — US disclosed
US-20200138718-A1 Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same LABORATORY SKIN CARE, INC. 2020-05-07 — — US disclosed
US-10350168-B2 Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same LABORATORY SKIN CARE, INC. (US) 2019-07-16 — — US disclosed
US-20170340566-A1 Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same LABORATORY SKIN CARE, INC. 2017-11-30 — — US disclosed
US-9707177-B2 Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same LABORATORY SKIN CARE, INC. (US) 2017-07-18 — — US disclosed
WO-2016110872-A1 FOOT CARE COMPOSITIONS Zydus Wellness Limited (IN) 2016-07-14 — — WO disclosed
US-20090068255-A1 USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE LIVING PROOF, INC. 2009-03-12 — — US disclosed
WO-2009023620-A2 COMPOSITIONS WITH PERFLUORINATED INGREDIENTS ELC MANAGEMENT LLC (US) 2009-02-19 — — WO disclosed
WO-2008134712-A2 USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE LIVING PROOF, INC. (US) 2008-11-06 — — WO disclosed
EP-1423448-A4 POLYMERIC URETHANE ESTER QUATS AND THEIR USE IN PERSONAL CARE COMPOSITIONS ALZO INT INC (US) 2005-06-29 — — EP disclosed
EP-1423448-A2 POLYMERIC URETHANE ESTER QUATS AND THEIR USE IN PERSONAL CARE COMPOSITIONS Alzo International, Inc. (US) 2004-06-02 — — EP disclosed
WO-2003016247-A2 POLYMERIC URETHANE ESTER QUATS AND THEIR USE IN PERSONAL CARE COMPOSITIONS ALZO INTERNATIONAL, INC. (US) 2003-02-27 — — WO disclosed
EP-1198447-A4 FATTY ACID ESTERS OF AROMATIC ALCOHOLS AND THEIR USE IN COSMETIC FORMULATIONS ALZO INC (US) 2002-09-04 — — EP disclosed
EP-1198447-A1 FATTY ACID ESTERS OF AROMATIC ALCOHOLS AND THEIR USE IN COSMETIC FORMULATIONS Alzo, Inc. (US) 2002-04-24 — — EP disclosed
US-6365629-B1 LIQUID DRY EMOLLIENTS ALTO, INC. 2002-04-02 — — US disclosed
WO-2000068176-A1 FATTY ACID ESTERS OF AROMATIC ALCOHOLS AND THEIR USE IN COSMETIC FORMULATIONS ALZO, INC. (US) 2000-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090068255-A1 USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE MMP1, MMP9, MMP17 MBOAT4 1413/4885CETP 3142/4885MEN1 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.